Indian stocks: Visit www.stage2stocks.com →

Replimune Group, Inc.

Stage 2 · Advancing · week 15

As of Oct 22, 2026, Replimune Group is in Stage 2, the uptrend phase, now in week 15 (since Jul 9, 2026). It closed at $11.99, 25.0% below its 52-week high and above its 200-day average, which is rising.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. More about the company

$11.99
+3.90% today
$1.1B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is REPL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 29w
S2 32w
S2 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S4 29w → S1 3w → S4 12w → S1 6w → S2 32w → S3 4w → S4 10w → S1 5w → S4 12w → S1 6w → S2 7w → S3 7w → S4 3w → S3 1w → S4 10w → S1 3w → S2 15w current
Total tracked: 166 weeks across 18 stage runs.

REPL among Biotechnology97th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…97REPLStage 2 · wk 1585−7.5%
vs 52W High
-25.0%
$1.70 lo$15.98 hi
25.0% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 15
1w13w26w
Week 15, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
31.8%
200 DMA: $9.10 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.76x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-7.5%
3M
+23.6%
6M
+320.7%
YTD
+34.7%
1Y
+48.0%
Scan Membership
Breakout Watch
Latest: 2024-08-07
8 appearances in last 60 days. First seen: 2019-05-14.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 15 · Vol 0.76x
2026-10-21S2
Wk 15 · Vol 0.73x
2026-10-20S2
Wk 15 · Vol 0.55x
2026-10-19S2
Wk 15 · Vol 0.58x
2026-10-16S2
Wk 15 · Vol 0.62x
2026-10-15S2
Wk 14 · Vol 0.58x
2026-10-14S2
Wk 14 · Vol 0.65x
2026-10-13S2
Wk 14 · Vol 0.53x
2026-10-12S2
Wk 14 · Vol 0.31x
2026-10-09S2
Wk 14 · Vol 0.55x
2026-10-08S2
Wk 13 · Vol 0.44x
2026-10-07S2
Wk 13 · Vol 0.37x
Moving averages & range
50 DMA
$13.60
200 DMA
$9.10
52W High
$15.98
52W Low
$1.70
5D Low
$10.86
Resistance levels (recent highs)
20d High
$13.45
60d High
$15.98
120d High
$15.98
250d High
$15.98
Next resistance
+12.2%
to 20d High
ROE
-134.3%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 9.5

Replimune Group: quick answers

What stage is Replimune Group in?

As of Oct 22, 2026, Replimune Group (REPL) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 9, 2026 and is in week 15. What the four stages mean

Is Replimune Group in an uptrend?

Yes. Replimune Group is in a Stage 2 uptrend. It trades 31.8% above its 200-day average, which is rising.

How far is Replimune Group from its 52-week high?

Replimune Group closed at $11.99 on Oct 22, 2026, 25.0% below its 52-week high of $15.98. Its 52-week low is $1.70.

How has Replimune Group performed over the past year?

As of Oct 22, 2026, Replimune Group is up 48.0% over the past year and up 34.7% so far in 2026.

Which sector and industry is Replimune Group in?

Replimune Group is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.